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Abstract
Objective
Biomedical investment trends in 2015 show a huge decrease of investment in gastroenter-
ology. Since academic research usually provides the basis for industrial research and
development (R&D), our aim was to understand research trends in the field of gastroenter-
ology over the last 50 years and identify the most endangered areas.
Methods
We searched for PubMed hits for gastrointestinal (GI) diseases for the 1965–2015 period.
Overall, 1,554,325 articles were analyzed. Since pancreatology was identified as the most
endangered field of research within gastroenterology, we carried out a detailed evaluation
of research activity in pancreatology.
Results
In 1965, among the major benign GI disorders, 51.9% of the research was performed on
hepatitis, 25.7% on pancreatitis, 21.7% on upper GI diseases and only 0.7% on the lower
GI disorders. Half a century later, in 2015, research on hepatitis and upper GI diseases had
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not changed significantly; however, studies on pancreatitis had dropped to 10.7%, while
work on the lower GI disorders had risen to 23.4%. With regard to the malignant disorders
(including liver, gastric, colon, pancreatic and oesophageal cancer), no such large-scale
changes were observed in the last 50 years. Detailed analyses revealed that besides the
drop in research activity in pancreatitis, there are serious problems with the quality of the
studies as well. Only 6.8% of clinical trials on pancreatitis were registered and only 5.5% of
these registered trials were multicentre and multinational (more than five centres and
nations), i.e., the kind that provides the highest level of impact and evidence level.
Conclusions
There has been a clear drop in research activity in pancreatitis. New international networks
and far more academic R&D activities should be established in order to find the first therapy
specifically for acute pancreatitis.
Introduction
Global biomedical research funding has started decreasing in the 21st century. The budget for the
NIH, which is the largest contributor to biomedical research, has steadily dropped from 2003 [1–
3]. Moreover, data on corporate investment trends published by the Biotechnology Industry
Organization in February 2015 showed a general decrease (from $21 billion (2004–2008) to $17
billion (2009–2013)) in research investment in novel drug research and development (R&D) and
drug improvement R&D [4]. However, investment trends in the different disease categories (car-
diovascular, immunology, gastroenterology, etc.) have been highly variable. Shockingly, the big-
gest drop was in the area of gastroenterology disease (62% from $828 million to $311 million), a
wake-up call to academic researchers to boost research activity in the field. Since academic
research usually provides the basis for industrial R&D, our aim was to understand the research
trends in the field of gastroenterology and highlight the most endangered areas.
Materials and Methods
Analyzing scientific activity in the different areas of gastroenterology
In the first part of the study, we searched PubMed hits between 1965 and 2015 for pancreatic
diseases (diabetes, pancreatitis and pancreatic cancer); benignGI diseases, such as upper GI
tract disorders (reflux, oeseophagitis, Barrett’s syndrome and gastritis), lower GI tract diseases
(inflammatory bowel diseases and irritable bowel syndrome) and hepatitis; and malignant GI
diseases, such as gastric, oesophageal, colon, liver and pancreatic cancers. Altogether, 1,554,325
articles were analyzed.
Detailed analyses of basic and clinical studies on pancreatitis and
pancreatic cancer
Since the biggest drop in research activity was in pancreatology, in the second part of the study
we aimed to search PubMed for ‘experimental pancreatitis’ (E-P; 3,767 articles were found),
‘experimental pancreatic cancer’ (E-PC; 3,697 articles), ‘pancreatitis AND clinical trial’ (C-P;
2,470), ‘pancreatic cancer AND clinical trial’ (C-PC; 4,321). Altogether, 14,255 articles were ana-
lyzed. All the available abstracts were checked. The final analyses were only performedon articles
which contained original data in pancreatic research (6,628) in the categories described above.
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After the exclusions, we conducted a detailed analysis of 1,871 articles in E-P, 1,726 in E-PC,
1,079 in C-P and 1,952 in C-PC. The following parameters were collected from the articles: (1)
number of countries and (2) number of centres involved in the research, (3) the journal’s impact
factor (IF; based on the last available IF for the journal) and (4) whether the trial was registered
in an official trial registry (only for clinical trials). An article was defined as ‘multinational’ if
more than five countries were involved in the study and ‘multicentre’ if more than five centres
took part. Analyses were performed for individual countries. An analysis of the individual
parameters was conducted on the group of articles where the given parameter was available.
All PubMed searches took place on 23 December 2015.
Limitations
The search was performed in PubMed, which provides a substantial selection of scientific liter-
ature, but of course it does not provide full coverage of all scientific activity. Another limitation
was the lack of information on specific parameters in some of the individual abstracts. These
abstracts were excluded from the analysis of that particular parameter. Finally, due to the
extremely high number of articles, the impact factors (IF) of the articles were not calculated for
the year of publication, but based on the journal’s IF for the most recent year (2014).
Statistical analysis
To investigate differences in research activity, we compared the confidence intervals (CI) of the
proportions.We used the equation for large samples,
p  z 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
pð1  pÞ
n
q
, where p ¼ mn , m = number of articles/disease and n = number of all
articles.
To analyze the changes of research activity, we compared the slopes of the regression with
an estimation of CI. One-way ANOVA was used with Dunnett’s post hoc test (unequal vari-
ances were assumed) to compare the IF between countries and centres. Chi-square tests were
employed for relationship analysis. Statistical analyses were done by IBM SPSS Statistics v 20.0
(IBMCorporation,Armonk, NY, USA).
Values are expressed as means ± standard error (S.E.M.) if not stated otherwise.A p value
<0.05 was considered statistically significant.
Data availability: Original data are available as supplementary materials (S1 and S2 Data).
Results
Research activity on pancreatitis has decreased compared to other
gastrointestinal diseases
In the first part of the study, we characterized research activity on different parts of the GI
tract. In 1965, among the major benignGI disorders, 51.9% (CI 49.58–54.22) of the research
was performed on hepatitis, 25.7% (CI 23.63–27.75) on pancreatitis, 21.7% (CI 19.76–23.30)
on upper GI diseases and only 0.7% (CI 0.34–1.13) on the lower GI disorders. Half a century
later, in 2015, twelve times more research was being carried out on benignGI disorders. How-
ever, while research on the lower GI tract had increased 383 times, that on hepatitis eleven
times and that on the upper GI tract ten times, the number of studies on pancreatitis had risen
only five times. These nonparallel changes led to a situation in which only 10.7% (CI 10.27–
11.11) of the research activity in 2015 was being performed on pancreatitis from among the
benignGI disorders (Fig 1A and 1B). Since research on the upper GI tract and hepatitis rose
parallel to the average increase of the research on the GI diseases, we can assume that the great
Research Activity in Gastroenterology in the Last 50 Years
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loss of interest in pancreatology was accompanied by a great upturn in research in the lower GI
disorders, namely, the IBD and IBS.
Research activity on pancreatic cancer has risen slightly compared to
other GI cancers
In 1965, among the major malignant GI disorders, research was conducted on the different forms
of cancer as follows: cancer of the liver: 33.9% (CI 31.89–35.93); the stomach: 29.1% (CI 27.18–
31.04); the colon: 14.6% (CI 13.05–16.05); the pancreas: 11.9% (CI 10.55–13.29); and the oesopha-
gus: 10.5% (CI 9.20–11.80). Fifty years later, in 2015, twelve timesmore research was being per-
formed on malignant GI disorders, an increase of exactly the same level as that of the studies on
the benignGI disorders.While the relative research activity on liver and oesophageal cancer did
not change, a clear decreasewas observed in studies on gastric cancer (from 29.1% to 20.2%), with
the biggest rise found in the research on pancreatic cancer (1.5 times) (Fig 1C and 1D).
Research activity on pancreatitis has decreased compared to that on
other major pancreatic disorders
Since the biggest drop in GI research interest was in the area of pancreatitis, we continued our
study by analyzing the trends in pancreatic diseases.Here we compared the changes of research
Fig 1. A–B. Inflammatory GI diseases. From 1965 to 2015, the great loss of interest in pancreatology was
accompanied by a major increase of research in the lower GI disorders, namely, the IBD and IBS. C–D. Malignant GI
diseases. The biggest increase was found in research activity on pancreatic cancer.
doi:10.1371/journal.pone.0165244.g001
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activity in diabetes, pancreatitis and pancreatic cancer. In 1965, 71.8% (CI 69.99–73.51) of the
research was performed on diabetes, 18.1% (CI 16.63–19.65) on pancreatitis and 10.1% (CI
8.93–11.29) on pancreatic cancer. Although 18 times more studies were being conducted on
the pancreas 50 years later, the relative interest in pancreatitis had dropped to 5% (CI 4.88–
5.28). The relative activity did not change verymuch in pancreatic cancer (from 10.1 to 11.2%);
however, research interest in the endocrine pancreas rose by 11.9% (Fig 2A and 2B). Analyzing
the dynamic of the changes, we can assume that the biggest rise in pancreatic research activity
in the last five years was in experimental pancreatic cancer. However, the number of clinical tri-
als–especially on pancreatitis–started decreasing (Fig 2C).
Fig 2. A–B. Pancreatic diseases. The relative interest in pancreatitis dropped from 18.1% to 5%. C. Dynamic of
pancreatic research. The biggest rise of pancreatic research activity in the last five years was in experimental
pancreatic cancer. However, the number of clinical trials–especially on pancreatitis–started decreasing.
doi:10.1371/journal.pone.0165244.g002
Research Activity in Gastroenterology in the Last 50 Years
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The USA, Germany and Japan publish the highest number of articles in
pancreatology
As stated above, 6,628 articles contained original research on basic or clinical pancreatology
(involving 7,927 countries). As regards the continents, 47.8% of all participation involved
Europe, 28.8% North America, 20.4% Asia and the Middle East, 1.2% Australia and Oceania,
1.2% South America and 0.5% Africa (Fig 3A). In terms of the four subgroups (E-P, E-PC, C-P
and C-PC), while Europe has the leading role in E-P, C-P and C-PC studies, North America
has the highest share in E-PC research. Among the subgroups, C-P has the lowest proportion
of all articles on all the continents (S1 Fig).
Fig 3. A. Published articles per continent. 47.8% of all the articles came from Europe and 28.8% from North
America. B. Published articles per country. The USA, Germany, Japan and China together account for more than
50% of all published articles in pancreatology.
doi:10.1371/journal.pone.0165244.g003
Research Activity in Gastroenterology in the Last 50 Years
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With regard to the location of research, not surprisingly, countries with the largest popula-
tion had an advantage: the USA was involved in the largest number of research articles
(26.8%), followed by Germany (10.4%), Japan (10.2%) and China (6.4%) (Fig 3B and Fig 4A).
Altogether, these four countries participated in more than 50% of the research on pancreatol-
ogy. Detailed analyses of the four subgroups revealed that the USA led all four subgroups. The
countries that ranked second in the subgroups were Germany in the experimental research
groups (E-P and E-PC), China in C-P and Japan in C-PC (S2 Fig).
The density of active pancreatic researchers is highest in the
Scandinavian countries
Comparing the data per population of 10 million, small countries came to the fore. Scandina-
vian countries are clearly the most active in pancreatic research per capita. None of the big
Fig 4. A. Map of published articles. The USA was involved in the largest number of research articles, followed by
Germany, Japan and China. B. Map of published articles per population. The Scandinavian countries are clearly
the most active in pancreatic research per capita.
doi:10.1371/journal.pone.0165244.g004
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countries were in the top five (Fig 4B). Detailed analysis has also revealed interesting differ-
ences between the countries (S3 Fig). E-P research is led by Finland, E-PC by Switzerland, C-P
by Denmark and C-PC by Sweden.
The USA and the Netherlands are in the forefront in registered clinical
trials
The highest level of evidence is obtained from registered clinical trials.With regard to the abso-
lute numbers of registered clinical trials in pancreatology, the big countries register the highest
number of trials (Fig 5A). Comparing registered clinical trials per population of 10 million,
Dutch researchers are the most active (Fig 5B). Only 13.4% of all trials were registered.
Fig 5. A. Map of registered trials. The big countries hold clear leading positions. B. Map of registered trials per
population. Comparing the registered clinical trials per population of 10 million, Dutch researchers are the most active.
doi:10.1371/journal.pone.0165244.g005
Research Activity in Gastroenterology in the Last 50 Years
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Multinational and multicentre studies provide the most valuable
research in pancreatology
Detailed analyses showed that there are no big differences between the average impact factors
(IF) of countries. Countries with a low number of articles, such as South Africa and Canada,
have the highest average IF. Over 30 countries produced an average IF higher than 5 (Fig 6A
and 6B). Therefore, practically speaking, the quality of research is not country-dependent.
However, detailed analysis of the articles revealed that there is a strong correlation between the
Fig 6. A. Map of average impact factor/country. There are no big differences between the average IF/country. B.
Average impact factor per country. Over 30 countries achieved an average IF higher than 5. Values are expressed
as means ± standard error (S.E.M.).
doi:10.1371/journal.pone.0165244.g006
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number of countries per study and the quality of the article. In a single-nation article, the aver-
age IF is 4.652 (± 0.10), when only a single centre is involved. However, the involvement of
more than six centres in a single nation increased the average IF of articles to 7.094 (± 0.37).
Notably, multicentre and multinational studies achieved the highest average impact 19.278 (±
2.55) (Fig 7A and 7B).
Fig 7. A. Average impact factor by number of centres and nations. Both multicentre and multinational approaches
increase the impact of the papers. *: p = 0.009 vs. single centre single nation; **: p<0.001 vs single centre/single nation;
***: p<0.001 vs 2–5 centres/2–5 nations and vs multicentre/single nation; ****: p<0.001 vs all groups. Values are
expressed as means ± standard error (S.E.M.) B. The share of average impact factor categories. There is a strong
correlation between the number of countries per study and the quality of the article.
doi:10.1371/journal.pone.0165244.g007
Research Activity in Gastroenterology in the Last 50 Years
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Discussion
With regard to gastrointestinal diseases, there is significantmorbidity, mortality and, of course,
spending within national health budgets [5–9]. In the USA, not only are 60–70 million people
affected by such diseases each year, but they also cause around a quarter million deaths annu-
ally and generate an estimated cost of $150 billion per year [7]. There is no specific therapy for
many of these diseases, including pancreatitis and pancreatic cancer [10–12]. Of course, first,
the pathomechanisms of the disease should be understood, new therapeutic targets revealed
and the biomedical industry attracted [13–16].
The levels of research activity in academia and the biomedical industry are remarkably
interdependent [17–19]. Gastroenterology is no longer attractive for investment by biomedical
firms or medical grant agencies [4]. Therefore, here we aimed to hold a mirror up to the
researchers and funding agencies to better understand the research activity in the field. Of
course, the hospitalization dynamics and requirements for different diseases in the areas of
gastroenterology differ. Since 2000, while some hospital admissions have decreased for certain
diseases (e.g. cholelithiasis by 14%, oesophageal reflux by 32% and alcoholic liver diseases by
5%) and others have risen (acute pancreatitis by 30%, clostridium difficile infection by 237%),
the highest number of admissions are due to acute pancreatitis (over 250,000/year), with the
highest annual costs ($2.5 billion) in the USA [7]. A Scottish study revealed a ten-fold rise in
the incidence of acute pancreatitis among men, and about half among women, from 1961 to
1985 [20]. After that, in the following ten years, it further increased around 65% [21]. More-
over, the incidence rate of chronic pancreatitis also rose. For example, within ten years, the hos-
pital admission rate for chronic pancreatitis doubled in the UK [22].
Therefore, needless to say, boosting research activity in the field of pancreatitis is not only
important medically but also economically. However, despite its great importance, pancreatic
research suffered the biggest loss of interest in gastroenterology, a trend which could be either
due to the lower activity in academic research and/or the lack of a specific therapy (i.e. no
income for the companies) for most of the diseases affecting either the endocrine or the exo-
crine pancreas.
What did we find and what can we do?
Strengths. It is clear from our analysis that both large and small countries are contributing
to pancreatic research. The literature on pancreatology is dominated by the United States, Ger-
many, China, Japan, Italy and the UK, just like in other scientific fields, such as ‘pain’ [23] and
‘oncology’ [24], whereas the density of pancreatic research is the highest in the Netherlands,
Finland, Sweden, Denmark and Hungary. We have observed a positive trend in the publication
of pancreatic cancer research, although the reason is definitely the multifactorial action plans,
such as those in the USA and Europe (www.pancan.org, www.eupancreas.com), which increase
awareness and may influence decisionmakers and promote grant funding [25].
Weaknesses. There are 50 countries in Europe, but only 23 are actively publishing in the
field (with more than ten published articles each in 50 years). The majority (84.8%) of the arti-
cles under analysis represent a single nation, and 39.9% are single-nation and single-centre
studies with no cooperationwith others. Not surprisingly, without cooperation, the possibilities
for data collectionwere limited; therefore, only a few high-quality multinational and multicen-
tre observational clinical trials or RCTs were performed [26–31]. It is important to highlight
that the Central and Eastern European, African, South American and Asian countries are fac-
ing the biggest difficulties as their sometimes poor infrastructure and lack of resources make
them an undesirable research partner. Moreover, grant proposals submitted from these coun-
tries are usually rejected.More than 50% of the European countries (representing more than
Research Activity in Gastroenterology in the Last 50 Years
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200 million people!) are only slightly involved in pancreatic research, a situation which is a
huge mistake and luxury in the field. In addition, patient care is also diminished since evi-
dence-based guidelines are only published in a few countries in Eastern and Central Europe
[32–37].
Opportunities. This analysis provides clear evidence that multicentre, multinational
cooperation can achieve better-quality trials and higher impact in the field. International
patient registries and biobanks should be created to stimulate quality multicentre observational
trials, RCTs and translational research [38–44]. Importantly, following the success of pancre-
atic cancer action plans that probably contributed to the four-fold rise of E-PC research activity
in the last few years, the same action should be initiated for pancreatitis.
Threats. If research on pancreatitis is to decrease further, journal editors may consider
pancreatology an even lower priority, thus resulting in fewer publications in top journals. Per-
haps it almost goes without saying that this will be followed by fewer grants and less activity in
the field, thus continuing the vicious circle seen in the last 50 years, which has resulted in no
specific treatment for acute pancreatitis.
Conclusion
Substantially more academic research should be performed in gastroenterology. Activity in
pancreatitis research has been rapidly decreasing. These data strongly suggest to funding agen-
cies that they should consider pancreatitis an endangered field of research and sponsor far
more international networks and academic R&D activities.
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